<DOC>
	<DOCNO>NCT02354443</DOCNO>
	<brief_summary>The purpose study describe safety profile ProHema-CB part single cord blood unit transplant myeloablative conditioning regimen pediatric patient inherit metabolic disorder . The safety profile primarily assess neutrophil engraftment .</brief_summary>
	<brief_title>A Trial Single ProHema-CB Product Transplant Pediatric Patients With Inherited Metabolic Disorders</brief_title>
	<detailed_description>This study open-label trial safety single cord blood transplant use ProHema-CB follow busulfan/cyclophosphamide/ATG condition pediatric patient inherit metabolic disorder . A maximum 12 eligible male female subject ( 1 18 year old , inclusive ) enrol treated trial approximately 1 3 center within U.S. All subject admit hospital , per institutional practice receive condition regimen , receive HLA-matched partially match ProHema -CB unit Day 0 . They receive study follow assessment weekly follow Day 0 Day 100 study visit Days 180 , 270 , 365 730 .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Metabolic Diseases</mesh_term>
	<criteria>1 . Patients must confirm diagnosis inherit metabolic disorder ( IMD ) amenable treatment hematopoietic cell transplantation : Mucopolysaccharidoses : Hurler Syndrome ( MPS IH ) , MPS IHS ( HurlerScheie Syndrome ) , Hunter Syndrome ( MPS II ) , Sanfilippo Syndrome ( MPS III ) , MPS VI ( MaroteauxLamy syndrome ) early neurologic involvement and/or sensitization enzyme replacement therapy ( ERT ) ; Leukodystrophies : Krabbe disease ( Globoid Leukodystrophy ) , Metachromatic Leukodystrophy ( MLD ) , Adrenoleukodystrophy ( ALD AMN ) ; Other IMD lysosomal storage disorder include glycoproteinoses ( AlphaMannosidosis , Mucolipidosis II ICell disease ) , sphingo lipidoses ( Sandhoff disease , Tay Sachs disease , Pelizaeus Merzbacher ( PMD ) , NiemannPick disease , GM1 gangliosidosis , Wolman 's disease . 2 . Male female subject age 1 18 year , inclusive . 3 . Lack 4 6/6 HLA match noncarrier relate UCB 8/8 HLA A , B , C , DRß1 match noncarrier related 8/8 unrelated bone marrow donor ; donor available within appropriate timeframe , determine transplant physician . 4 . Availability suitable primary secondary umbilical cord blood ( UCB ) unit . 5 . Adequate performance status , define : Subjects ≥ 16 year : Karnofsky score ≥ 70 % . Subjects &lt; 16 year : Lansky score ≥ 70 % . 6 . Cardiac : Left ventricular ejection fraction rest must &gt; 40 % , shorten fraction &gt; 26 % . 7 . Pulmonary : Subjects &gt; 10 year : DLCO ( diffusion capacity ) &gt; 50 % predict ( correct hemoglobin ) FEV1 , FVC &gt; 50 % predict ; Note : If unable perform pulmonary test , O2 saturation &gt; 92 % room air . 8 . Renal : Serum creatinine within normal range age , serum creatinine outside normal range age , renal function ( creatinine clearance GFR ) &gt; 70mL/min/1.73m2 . 9 . Hepatic : Bilirubin ≤ 2.5 mg/dL ( except case Gilbert 's syndrome , ongoing hemolytic anemia , due primary IMD ) ; ALT , AST Alkaline Phosphatase ≤ x 3 ULN ( elevation beyond ULN must secondary primary IMD comorbid condition ) . 10 . Signed IRB approve Informed Consent Form ( ICF ) . 1 . Evidence HIV infection HIV positive serology . 2 . Current uncontrolled bacterial , viral fungal infection ( progression clinical symptom despite therapy ) . 3 . Requirement continuous respiratory supportive therapy ( e.g . ventilator ) . Patients intermittent respiratory support discuss Sponsor . 4 . Active problem relate chronic aspiration . 5 . Uncontrolled seizure . 6 . Any active malignancy myelodysplastic syndrome history malignancy . 7 . Inability give inform consent/assent comply requirement care allogeneic stem cell transplantation . 8 . Female subject breastfeed positive pregnancy ( HCG ) test Screening . 9 . Use investigational drug within 30 day prior screen primary IMD .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>